AAN: Modafinil (Provigil) Helps Sleepy Parkinson’s Disease Patients Stay Awake
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




AAN: Modafinil (Provigil) Helps Sleepy Parkinson’s Disease Patients Stay Awake

By Jill Stein
Special to DG News

PHILADELPHIA, PA -- May 10, 2001 -- The novel wake-promoting agent Provigil (modafinil) is an effective treatment for excessive daytime sleepiness in patients with Parkinson’s disease, investigators have found.

The data were reported at the 53rd Annual Meeting of the American Academy of Neurology by researchers from the Mayo Clinic in Scottsdale, Arizona.

Results were drawn from a study involving 20 Parkinson’s disease patients who had a baseline Epworth Sleepiness Scale (ESS) score of greater than or equal to 10.

Subjects were randomized to treatment with modafinil 200 mg/day or placebo for three weeks, followed by a washout week and then the alternate treatment for three weeks.

The primary outcome measure was the change in ESS score.

The mean ESS score for the placebo group increased from a baseline of 16.0 to 17.0 after treatment. For the modafinil group, the mean ESS score was 17.8 at baseline and 14.4 after treatment, for an overall improvement of 25 percent, said Dr. Charles Adler, professor of neurology and co-director of the Mayo Clinic’s Parkinson’s Disease and Movement Disorders Center.

The patient-rated Clinical Global Impression of Change (CGI-C), a secondary outcome measure, improved by 0.75 with modafinil treatment compared with 0.15 for placebo.

Overall, seven (35 percent) patients reported definite improvement during modafinil treatment compared with one (five percent) patient during placebo treatment and two (10 percent) patients on both modafinil and placebo.

Dr. Adler said that the improvement in mean ESS score in Parkinson’s disease patients during modafinil treatment is similar to that which has been reported in narcolepsy patients.

Related Link: Provigil (modafinil).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities